Mesenchymal Stem Cells Prevent SLC39A14‐Dependent Hepatocyte Ferroptosis through Exosomal miR‐16‐5p in Liver Graft
Advanced Science · 2025-02 · 12 (6)
DOI: 10.1002/advs.202411380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.12.2024. Verfasst von Zhizhao Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, China. Hauptthemen laut MEDLINE: Ferroptosis, Hepatocytes, Mesenchymal Stem Cells, MicroRNAs. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Joint Funds of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Ischemia‐reperfusion injury (IRI) is the leading cause of hepatic graft dysfunction, resulting from hepatocyte damage. Nevertheless, given the few specialized therapeutics available in hepatic IRI, additional mechanistic insights into hepatocyte damage are required. Here, the protein solute carrier family 39 member 14 (SLC39A14) is identified as a pro‐ferroptosis target in hepatocytes of human liver allografts through single‐cell RNA sequencing analysis. SLC39A14 knockdown significantly mitigated hepatic IRI by preventing hepatocyte ferroptosis in vivo and in vitro. Mechanistically, the inhibition of SLC39A14 suppressed non‐transferrin‐bound iron (NTBI) uptake by hepatocytes, thereby reducing iron overload and cell ferroptosis. Moreover, human bone marrow‐derived mesenchymal stem cells (hBMSCs) are found to exhibit a notable therapeutic effect on hepatic IRI by downregulating SLC39A14 expression. Exosomes derived from hBMSCs delivered abundant miR‐16‐5p into hepatocytes, which post‐transcriptionally suppressed the expression of SLC39A14 and reduced cell ferroptosis induced by hepatic IRI. In conclusion, SLC39A14 triggers hepatic IRI by mediating NTBI uptake into hepatocytes and inducing hepatocyte ferroptosis. Moreover, hBMSC‐based therapy is promising to reverse this progression of hepatic IRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, China.
ORCID-Profile: Dongdong Yuan
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Joint Funds of the National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province-Regional Innovation Capacity and Support System Construction
- Provincial-enterprise Joint Funds of Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Program of Guangzhou, China
- The "Five and five" Project of the Third Affiliated Hospital of Sun Yat-Sen University
Zitieren
APA
Deng, Z., Zeng, W., Gao, Y., Yang, Z., Luo, X., Li, X., Sun, G., Xiong, E., Huang, F., Luo, G., Hei, Z., & Yuan, D. (2025). Mesenchymal Stem Cells Prevent SLC39A14‐Dependent Hepatocyte Ferroptosis through Exosomal miR‐16‐5p in Liver Graft. Advanced Science, 12(6). https://doi.org/10.1002/advs.202411380
Vancouver
Deng Z, Zeng W, Gao Y, Yang Z, Luo X, Li X, et al. Mesenchymal Stem Cells Prevent SLC39A14‐Dependent Hepatocyte Ferroptosis through Exosomal miR‐16‐5p in Liver Graft. Advanced Science. 2025;12(6). doi:10.1002/advs.202411380
BibTeX
@article{Deng2025,
author = {Deng, Zhizhao and Zeng, Weiqi and Gao, Yingxin and Yang, Zhenyu and Luo, Xinling and Li, Xianlong and Sun, Guoliang and Xiong, Erfeng and Huang, Fei and Luo, Gangjian and Hei, Ziqing and Yuan, Dongdong},
title = {Mesenchymal Stem Cells Prevent SLC39A14‐Dependent Hepatocyte Ferroptosis through Exosomal miR‐16‐5p in Liver Graft},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {6},
doi = {10.1002/advs.202411380}
}
EUVIMED